Cancer Drug May Increase Patient Survival, Oxford BioMedica PLC Says

(Reuters) - Oxford BioMedica said on Friday a cross-trial analysis of its experimental drug TroVax in colorectal, renal and prostate cancer showed a positive correlation between immune response and patient survival.

MORE ON THIS TOPIC